Ingen Technologies, Inc.

Ingen Technologies, Inc., a medical device manufacturing company, manufactures medical products for the respiratory industry in United States. The company manufactures medical equipment for patients suffering with chronic obstructive pulmonary disease; and oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademark name. Its Oxyview is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient. Ingen Technologies, Inc. was founded in 1999 and is based in Riverside, California.

Ingen Technologies, Inc. trades as IGNT on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $13.565 of revenue and -$1,012 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Ingen Technologies, Inc. can be compared against peers such as Acutus Medical, Inc., Allstar Health Brands, Inc., Aridis Pharmaceuticals, Inc., Capital Group Holdings, Inc., Infinity Pharmaceuticals, Inc., ChromoCure, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1,792, beta of -7.80, and return on equity of +9.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IGNT currently shows total debt of $6,707 and beta of -7.80. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ingen-tech.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.